Adjunct methods of the standard diabetic foot ulceration therapy

Dariusz Waniczek, Andrzej Kozowicz, Małgorzata Muc-Wierzgoń, Teresa Kokot, Elżbieta Swiętochowska, Ewa Nowakowska-Zajdel, Dariusz Waniczek, Andrzej Kozowicz, Małgorzata Muc-Wierzgoń, Teresa Kokot, Elżbieta Swiętochowska, Ewa Nowakowska-Zajdel

Abstract

The outcome of management of diabetic foot ulceration (DFU) is poor and insufficient. DFU therapy includes the standard management as debridement of the wound, revascularization procedures, off-loading of the ulcer and antibacterial actions, and supplementation of growth factors and cytokines, leading to stimulation of granulation, epidermization, and angiogenesis. The aim of the present review is to summarize the adjunct methods of the standard DFU therapy as hyperbaric oxygen therapy (HBOT), maggot therapy (MT), and platelet-rich plasma therapy (PRPT). The results of preclinical and clinical trials indicated that the methods may reduce time of therapy, short-term morbidity, and the risk of major amputation.

References

    1. IDF Diabetes Atlas. 5th edition 2012.
    1. Bruhn-Olszewska B, Korzon-Burakowska A, Gabig-Cimińska M, Olszewski P, Wegrzyn A, Jakóbkiewicz-Banecka J. Molecular factors involved in the development of diabetic foot syndrome. Acta Biochimica Polonica. 2012;59(4):507–513.
    1. Cornell S, Dorsey VJ. Diabetes pharmacotherapy in 2012: considerations in medication selection. Postgraduate Medicine. 2012;124:84–94.
    1. Iversen MM. An Epidemiologic Study of Diabetes-Related Foot Ulcers. Bergen, Norway: Department of Public Health and Primary Health Care; 2009.
    1. Brem H, Sheehan P, Boulton AJM. Protocol for treatment of diabetic foot ulcers. The American Journal of Surgery. 2004;187(5):1–10.
    1. Krishnan S, Nash F, Baker N, Fowler D, Rayman G. Reduction in diabetic amputations over 11 years in a defined U.K. population: benefits of multidisciplinary team work and continuous prospective audit. Diabetes Care. 2008;31(1):99–101.
    1. Bolton L, McNees P, van Rijswijk L, et al. Wound-healing outcomes using standardized assessment and care in clinical practice. Journal of Wound, Ostomy, and Continence Nursing. 2004;31(2):65–71.
    1. Boulton AJM, Cavanagh PR, Rayman G. The Foot in Diabetes. 4th edition. New York, NY, USA: John Wiley & Sons; 2006.
    1. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. The Journal of the American Medical Association. 2005;293(2):217–228.
    1. Boulton AJM. The pathogenesis of diabetic foot problems: an overview. Diabetic Medicine. 1996;13(1):S12–S16.
    1. Ndip A, Jude EB. Emerging evidence for neuroischemic diabetic foot ulcers: model of care and how to adapt practice. International Journal of Lower Extremity Wounds. 2009;8(2):82–94.
    1. Ribu L, Hanestad BR, Moum T, Birkeland K, Rustoen T. A comparison of the health-related quality of life in patients with diabetic foot ulcers, with a diabetes group and a nondiabetes group from the general population. Quality of Life Research. 2007;16(2):179–189.
    1. Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22(3):382–387.
    1. Bakker K, Apelqvist J, Schaper NC. Practical guidelines on the management and prevention of the diabetic foot 2011. Diabetes/Metabolism Research and Reviews. 2012;28(1):225–231.
    1. Wagner FW., Jr. The dysvascular foot: a system for diagnosis and treatment. Foot and Ankle. 1981;2(2):64–122.
    1. Lavery LA. Effectiveness and safety of elective surgical procedures to improve wound healing and reduce re-ulceration in diabetic patients with foot ulcers. Diabetes/Metabolism Research and Reviews. 2012;28(1):60–63.
    1. Baroni G, Porro T, Faglia E, et al. Hyperbaric oxygen in diabetic gangrene treatment. Diabetes Care. 1987;10(1):81–86.
    1. Zamboni WA, Wong HP, Stephenson LL, Pfeifer MA. Evaluation of hyperbaric oxygen for diabetic wounds: a prospective study. Undersea and Hyperbaric Medicine. 1997;24(3):175–179.
    1. Faglia E, Favales F, Aldeghi A, et al. Change in major amputation rate in a center dedicated to diabetic foot care during the 1980s: prognostic determinants for major amputation. Journal of Diabetes and Its Complications. 1998;12(2):96–102.
    1. Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer: a randomized study. Diabetes Care. 1996;19(12):1338–1343.
    1. Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plastic and Reconstructive Surgery. 2011;127(1):131–141.
    1. Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach. Undersea and hyperbaric Medicine. 2002;29(1):4–30.
    1. Niinikoski JHA. Clinical hyperbaric oxygen therapy, wound perfusion, and transcutaneous oximetry. World Journal of Surgery. 2004;28(3):307–311.
    1. Ackerman NB, Brinkley FB. Oxygen tensions in normal and ischemic tissues during hyperbaric therapy. Studies in rabbits. The Journal of the American Medical Association. 1966;198(12):1280–1283.
    1. Löndahl M, Katzman P, Hammarlund C, Nilsson A, Landin-Olsson M. Relationship between ulcer healing after hyperbaric oxygen therapy and transcutaneous oximetry, toe blood pressure and ankle-brachial index in patients with diabetes and chronic foot ulcers. Diabetologia. 2011;54(1):65–68.
    1. Heinzelmann M, Scott M, Lam T. Factors predisposing to bacterial invasion and infection. The American Journal of Surgery. 2002;183(2):179–190.
    1. Mader JT, Brown GL, Guckian JC, Wells CH, Reinarz JA. A mechanism for the amelioration by hyperbaric oxygen of experimental staphylococcal osteomyelitis in rabbits. Journal of Infectious Diseases. 1980;142(6):915–922.
    1. Heng MC, Harker J, Csathy G, et al. Angiogenesis in necrotic ulcers treated with hyperbaric oxygen. Ostomy/Wound Management. 2000;46(9):18–32.
    1. Thom SR, Milovanova TN, Yang M, et al. Vasculogenic stem cell mobilization and wound recruitment in diabetic patients: Increased cell number and intracellular regulatory protein content associated with hyperbaric oxygen therapy. Wound Repair and Regeneration. 2011;19(2):149–161.
    1. Ramon Y, Abramovich A, Shupak A, et al. Effect of hyperbaric oxygen on a rat transverse rectus abdominis myocutaneous flap model. Plastic and Reconstructive Surgery. 1998;102(2):416–422.
    1. Selçuk CT, Kuvat SV, Bozkurt M, et al. The effect of hyperbaric oxygen therapy on the survival of random pattern skin flaps in nicotine-treated rats. Journal of Plastic, Reconstructive and Aesthetic Surgery. 2012;65(4):489–493.
    1. Kranke P, Bennett M, Roeckl-Wiedmann I, Debus SE. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database of Systematic Reviews. 2004;(2)CD004123
    1. Löndahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care. 2010;33(5):998–1003.
    1. Duzgun AP, Satir HZ, Ozozan O, Saylam B, Kulah B, Coskun F. Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers. Journal of Foot and Ankle Surgery. 2008;47(6):515–519.
    1. Abidia A, Laden G, Kuhan G, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomized-controlled trial. European Journal of Vascular and Endovascular Surgery. 2003;25(6):513–518.
    1. Kalani M, Jörneskog G, Naderi N, Lind F, Brismar K. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers—long-term follow-up. Journal of Diabetes and Its Complications. 2002;16(2):153–158.
    1. Doctor N, Pandya S, Supe A. Hyperbaric oxygen therapy in diabetic foot. Journal of Postgraduate Medicine. 1992;38(3):112–111.
    1. Oriani G, Meazza D, Favales F, et al. Hyperbaric oxygen in diabetic gangrene. Journal of Hyperbaric Medicine. 1990;5:171–175.
    1. Hammarlund C, Sundberg T. Hyperbaric oxygen reduced size of chronic leg ulcers: a randomized double-blind study. Plastic and Reconstructive Surgery. 1994;93(4):829–833.
    1. Lyon KC. The case for evidence in wound care: investigating advanced treatment modalities in healing chronic diabetic lower extremity wounds. Journal of Wound Ostomy and Continence Nursing. 2008;35(6):585–590.
    1. Wunderlich RP, Peters EJG, Lavery LA. Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot. Diabetes Care. 2000;23(10):1551–1555.
    1. Prete PE. Growth effects of Phaenicia sericata larval extracts on fibroblasts: mechanism for wound healing by maggot therapy. Life Sciences. 1997;60(8):505–510.
    1. Gupta A. A review of the use of maggots in wound therapy. Annals of Plastic Surgery. 2008;60(2):224–227.
    1. Jarczyk G, Jackowski M, Szpila K, Boszek G, Kapelaty S. Use of Lucilia sericata blowfly maggots in the treatment of diabetic feet threatened with amputation. Acta Angiologica. 2008;14(2):42–55.
    1. Sherman RA. Maggot therapy for treating diabetic foot ulcers unresponsive to conventional therapy. Diabetes Care. 2003;26(2):446–451.
    1. Armstrong DG, Salas P, Short B, et al. Maggot therapy in “lower-extremity hospice” wound care: fewer amputations and more antibiotic-free days. Journal of the American Podiatric Medical Association. 2005;95(3):254–257.
    1. Bowling FL, Salgami EV, Boulton AJM. Larval therapy: a novel treatment in eliminating methicillin-resistant Staphylococcus aureus from diabetic foot ulcers. Diabetes Care. 2007;30(2):370–371.
    1. Chan DCW, Fong DHF, Leung JYY, Patil NG, Leung GKK. Maggot debridement therapy in chronic wound care. Hong Kong Medical Journal. 2007;13(5):382–386.
    1. Game FL, Hinchliffe RJ, Apelqvist J, et al. A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes/Metabolism Research and Reviews. 2012;28(1):119–141.
    1. Ross R, Glomset J, Kariya B, Harker L. A platelet dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proceedings of the National Academy of Sciences of the United States of America. 1974;71(4):1207–1210.
    1. Cenni E, Ciapetti G, Pagani S, Perut F, Giunti A, Baldini N. Effects of activated platelet concentrates on human primary cultures of fibroblasts and osteoblasts. Journal of Periodontology. 2005;76(3):323–328.
    1. Kark LR, Karp JM, Davies JE. Platelet releasate increases the proliferation and migration of bone marrow-derived cells cultured under osteogenic conditions. Clinical Oral Implants Research. 2006;17(3):321–327.
    1. Borzini P, Mazzucco I. Platelet-rich plasma (PRP) and platelet derivatives for topical therapy. What is true from the biologic view point? ISBT Science Series. 2007;2(1):272–281.
    1. Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. Classification and treatment of chronic nonhealing wounds: successful treatment with autologous platelet-derived wound healing factors (PDWHF) Annals of Surgery. 1986;204(3):322–330.
    1. Pietramaggiori G, Scherer SS, Mathews JC, et al. Healing modulation induced by freeze-dried platelet-rich plasma and micronized allogenic dermis in a diabetic wound model. Wound Repair and Regeneration. 2008;16(2):218–225.
    1. Knighton DR, Hunt TK, Thakral KK, Goodson WH., III Role of platelets and fibrin in the healing sequence. An in vivo study of angiogenesis and collagen synthesis. Annals of Surgery. 1982;196(4):379–388.
    1. Krupski WC, Reilly LM, Perez S, Moss KM, Crombleholme PA, Rapp JH. A prospective randomized trial of autologous platelet-derived wound healing factors for treatment of chronic nonhealing wounds: a preliminary report. Journal of Vascular Surgery. 1991;14(4):526–536.
    1. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care. 2001;24(3):483–488.
    1. McAleer JP, Sharma S, Kaplan EM, Persich G. Use of autologous platelet concentrate in a nonhealing lower extremity wound. Advances in Skin & Wound Care. 2006;19(7):354–363.
    1. Driver VR, Hanft J, Fylling CP, Beriou JM, Autologel Diabetic Foot Ulcer Study Group A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy/Wound Management. 2006;52(6):68–74.
    1. Gandhi A, Doumas C, O'Connor JP, Parsons JR, Lin SS. The effects of local platelet rich plasma delivery on diabetic fracture healing. Bone. 2006;38(4):540–546.
    1. Scimeca CL, Bharara M, Fisher TK, Kimbriel H, Armstrong DG. Novel use of platelet-rich plasma to augment curative diabetic foot surgery. Journal of Diabetes Science and Technology. 2010;4(5):1121–1126.
    1. Villela DL, Santos VLCG. Evidence on the use of platelet-rich plasma for diabetic ulcer: a systematic review. Growth Factors. 2010;28(2):111–116.
    1. Frykberg RG, Driver VR, Carman D, et al. Chronic wounds treated with a physiologically relevant concentration of platelet-rich plasma gel: a prospective case series. Ostomy/Wound Management. 2010;56(6):36–44.
    1. Carter MJ, Fylling CP, Parnell LK. Use of platelet rich plasma gel on wound healing: a systematic review and meta-analysis. Eplasty. 2011;11(article e38)
    1. de Leon JM, Driver VR, Fylling CP, et al. The clinical relevance of treating chronic wounds with an enhanced near-physiological concentration of platelet-rich plasma gel. Advances in Skin & Wound Care. 2011;24(8):357–368.
    1. Slesaczeck T, Paetzold H, Nanning T, et al. Autologous derived, platelet-rich plasma gel in the treatment of nonhealing diabetic foot ulcer: a case report. Therapeutic Advances in Endocrinology and Metabolism. 2012;3(2):75–78.
    1. Kessler L, Bilbault P, Ortéga F, et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers a prospective randomized study. Diabetes Care. 2003;26(8):2378–2382.
    1. Roeckl-Wiedmann I, Bennett M, Kranke P. Systematic review of hyperbaric oxygen in the management of chronic wounds. The British Journal of Surgery. 2005;92(1):24–32.
    1. Löndahl M, Landin-Olsson M, Katzman P. Hyperbaric oxygen therapy improves health-related quality of life in patients with diabetes and chronic foot ulcer. Diabetic Medicine. 2011;28(2):186–190.
    1. Löndahl M. Hyperbaric oxygen therapy as treatment of diabetic foot ulcers. Diabetes/Metabolism Research and Reviews. 2012;28(supplement1):78–84.
    1. Liu R, Li L, Yang M, Boden G, Yang G. Systematic review of the effectiveness of hyperbaric oxygenation therapy in the management of chronic diabetic foot ulcers. Mayo Clinic Proceedings. 2013;88(2):166–175.
    1. Jeffcoate WJ. Wound healing-a practical algorithm. Diabetes/Metabolism Research and Reviews. 2012;28(supplement 1):85–88.
    1. Gordon KA, Lebrun EA, Tomic-Canic M, Kirsner RS. The role of surgical debridement in healing of diabetic foot ulcers. Skinmed. 2012;10(1):24–26.
    1. van der Plas MJA, Baldry M, van Dissel JT, Jukema GN, Nibbering PH. Maggot secretions suppress pro-inflammatory responses of human monocytes through elevation of cyclic AMP. Diabetologia. 2009;52(9):1962–1970.
    1. Sherman RA. Maggot therapy takes us back to the future of wound care: new and improved maggot therapy for the 21st century. Journal of Diabetes Science and Technology. 2009;3(2):336–344.
    1. Mumcuoglu KY, Miller J, Mumcuoglu M, Friger M, Tarshis M. Destruction of bacteria in the digestive tract of the maggot of Lucilia sericata (Diptera: Calliphoridae) Journal of Medical Entomology. 2001;38(2):161–166.
    1. Jiang KC, Sun XJ, Wang W, et al. Excretions/secretions from bacteria-pretreated maggot are more effective against Pseudomonas aeruginosa biofilms. PloS ONE. 2012;7(11)e49815
    1. Arora S, Baptista C, Lim CS. Maggot metabolites and their combinatory effects with antibiotic on Staphylococcus aureus . Annals of Clinical Microbiology and Antimicrobials. 2011;10, article 6
    1. Courtenay M, Church JCT, Ryan TJ. Larva therapy in wound management. Journal of the Royal Society of Medicine. 2000;93(2):72–74.
    1. Dumville JC, Worthy G, Bland JM, et al. Larval therapy for leg ulcers (VenUS II): randomised controlled trial. The British Medical Journal. 2009;338(article b773)
    1. Mumcuoglu KY. Clinical applications for maggots in wound care. The American Journal of Clinical Dermatology. 2001;2(4):219–227.
    1. Li GY, Yin JM, Ding H, Jia WT, Zhang CQ. Efficacy of leukocyte-and platelet-rich plasma gel (L-PRP gel) in treating osteomyelitis in a rabbit model. Journal of Orthopaedic Research. 2013;31(6):946–956.
    1. Gottrup F, Jorgensen B. Maggot debridement: an alternative method for debridement. Journal of Plastic Surgery. 2011;11:290–300.
    1. Baer WS. Treatment of chronic osteomyelitis with the maggot (larve of the blowfly) Journal of Bone and Joint Surgery. 1931;13(3):438–475.
    1. Paul AG, Ahmad NW, Lee H, et al. Maggot debridement therapy with Lucilia cuprina: a comparison with conventional debridement in diabetic foot ulcers. International Wound Journal. 2009;6(1):39–46.
    1. Paul AG, Ahmad NW, Lee H, et al. Maggot debridement therapy with Lucilia cuprina: a comparison with conventional debridement in diabetic foot ulcers. International Wound Journal. 2009;6(1):39–46.
    1. Dumville JC, Worthy G, Bland JM, et al. Larval therapy for leg ulcers (VenUS II): randomised controlled trial. The British Medical Journal. 2009;338(article b773)
    1. Sherman RA, Sherman J, Gilead L, Lipo M, Mumcuoglu KY. Maggot débridement therapy in outpatients. Archives of Physical Medicine and Rehabilitation. 2001;82(9):1226–1229.
    1. Soares MO, Iglesias CP, Bland JM, et al. Cost effectiveness analysis of larval therapy for leg ulcers. The British Medical Journal. 2009;338(article b825)
    1. Nigam Y, Bexfield A, Thomas S, Ratcliffe NA. Maggot therapy: the science and implication for CAM Part I—history and bacterial resistance. Evidence-Based Complementary and Alternative Medicine. 2006;3(2):223–227.
    1. Mehta S, Watson JT. Platelet rich concentrate: basic science and current clinical applications. Journal of Orthopaedic Trauma. 2008;22(6):433–438.
    1. Heldin C, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiological Reviews. 1999;79(4):1283–1316.
    1. Gandhi A, Bibbo C, Pinzur M, Lin SS. The role of platelet-rich plasma in foot and ankle surgery. Foot and Ankle Clinics. 2005;10(4):621–637.
    1. Everts PAM, Mahoney CB, Hoffmann JJML, et al. Platelet-rich plasma preparation using three devices: implications for platelet activation and platelet growth factor release. Growth Factors. 2006;24(3):165–171.
    1. Everts PAM, Hoffmann J, Weibrich G, et al. Differences in platelet growth factor release and leucocyte kinetics during autologous platelet gel formation. Transfusion Medicine. 2006;16(5):363–368.
    1. Marx RE. Platelet-rich plasma: evidence to support its use. Journal of Oral and Maxillofacial Surgery. 2004;62(4):489–496.
    1. Bielecki TM, Gazdzik TS, Arendt J, Szczepanski T, Król W, Wielkoszynski T. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: an in vitro study. Journal of Bone and Joint Surgery B. 2007;89(3):417–420.
    1. Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale Journal of Biology and Medicine. 2010;83(1):1–9.
    1. Heldin C, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiological Reviews. 1999;79(4):1283–1316.
    1. Gandhi A, Bibbo C, Pinzur M, Lin SS. The role of platelet-rich plasma in foot and ankle surgery. Foot and Ankle Clinics. 2005;10(4):621–637.
    1. Slesaczeck T, Paetzold H, Nanning T, et al. Autologous derived, platelet-rich plasma gel in the treatment of nonhealing diabetic foot ulcer: a case report. Therapeutic Advances in Endocrinology and Metabolism. 2012;3(2):75–78.
    1. Dougherty EJ. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers. Advances in Skin & Wound Care. 2008;21(12):568–575.
    1. Lynch SE, Williams RC, Polson AM, et al. A combination of platelet-derived and insulin-like growth factors enhances periodontal regeneration. Journal of Clinical Periodontology. 1989;16(8):545–548.
    1. LeGrand EK, Burke JF, Costa DE, Kiorpes TC. Dose responsive effects of PDGF-BB, PDGF-AA, EGF, and bFGF on granulation tissue in a guinea pig partial thickness skin excision model. Growth Factors. 1993;8(4):307–314.
    1. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiological Reviews. 1999;79(4):1283–1316.
    1. Pavlovich CP, Battiwalla M, Rick ME, Walther MM. Antibody induced coagulopathy from bovine thrombin use during partial nephrectomy. Journal of Urology. 2001;165(5, article 1617)
    1. Doupis J, Veves A. Classification, diagnosis, and treatment of diabetic foot ulcers. Wounds. 2008;20(5):117–128.
    1. Alexiadou K, Doupis J. Management of diabetic foot ulcers. Diabetes Therapy. 2012;3(1, article 4)
    1. Li GY, Yin JM, Ding H, Jia WT, Zhang CQ. Efficacy of leukocyte-and platelet-rich plasma gel (L-PRP gel) in treating osteomyelitis in a rabbit model. Journal of Orthopaedic Research. 2013;31(6):949–956.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner